Ultimovacs ASA (STU:7UM) Cash-to-Debt : 61.78 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ultimovacs ASA Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ultimovacs ASA's cash to debt ratio for the quarter that ended in Mar. 2024 was 61.78.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ultimovacs ASA could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Ultimovacs ASA's Cash-to-Debt or its related term are showing as below:

STU:7UM' s Cash-to-Debt Range Over the Past 10 Years
Min: 61.78 Med: 127.39 Max: No Debt
Current: 61.78

During the past 9 years, Ultimovacs ASA's highest Cash to Debt Ratio was No Debt. The lowest was 61.78. And the median was 127.39.

STU:7UM's Cash-to-Debt is ranked better than
74.66% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs STU:7UM: 61.78

Ultimovacs ASA Cash-to-Debt Historical Data

The historical data trend for Ultimovacs ASA's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ultimovacs ASA Cash-to-Debt Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

110.40

116.60

276.00

77.55

71.73

Ultimovacs ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															80.39	74.67	71.92	71.73	61.78

Competitive Comparison of Ultimovacs ASA's Cash-to-Debt

For the Biotechnology subindustry, Ultimovacs ASA's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ultimovacs ASA's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultimovacs ASA's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ultimovacs ASA's Cash-to-Debt falls into.

Ultimovacs ASA Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ultimovacs ASA's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	23.17	/	(0.159	+	0.164)
	=	71.73

Ultimovacs ASA's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	19.153	/	(0.167	+	0.143)
	=	61.78

Ultimovacs ASA (STU:7UM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ultimovacs ASA Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (STU:7UM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (STU:7UM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden ULTI:Norway

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (STU:7UM) Headlines

No Headlines